+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Patient-Derived Xenograft/PDX Model Market by Type (Mice Models, Rat Models), Tumor Type (Gastrointestinal, Gynecological, Hematological), Study Type, Implantation Method, Application, End-User - Global Forecast 2025-2030- Product Image
Patient-Derived Xenograft/PDX Model Market by Type (Mice Models, Rat Models), Tumor Type (Gastrointestinal, Gynecological, Hematological), Study Type, Implantation Method, Application, End-User - Global Forecast 2025-2030- Product Image
Sale

Patient-Derived Xenograft/PDX Model Market by Type (Mice Models, Rat Models), Tumor Type (Gastrointestinal, Gynecological, Hematological), Study Type, Implantation Method, Application, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • March 2025
  • Region: Global
  • 360iResearch™
  • ID: 5637019
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Patient-Derived Xenograft/PDX Model Market grew from USD 383.38 million in 2023 to USD 429.04 million in 2024. It is expected to continue growing at a CAGR of 12.27%, reaching USD 862.31 million by 2030.

Patient-derived xenograft (PDX) models stand at the forefront of translational cancer research, bridging a critical gap between laboratory experiments and clinical applications. These models, derived directly from patient tumors, faithfully mimic the original tumor’s properties, offering a vital tool in studying cancer biology, drug responses, and personalized treatment strategies. In recent years, the adoption of PDX models has surged as researchers and pharmaceutical companies alike seek to enhance the predictability of preclinical studies. This innovative approach not only refines our understanding of tumor behavior but also reduces the attrition rate during drug development, ensuring that treatments are more efficiently tailored to individual patient profiles.

The evolution of PDX models reflects a broader trend where precision medicine meets cutting-edge biotechnology. As advances in molecular profiling and genomic analysis continue to enrich our insight into cancer’s complexity, PDX models remain indispensable. They serve as a dynamic platform that integrates real-world patient data into research, thus ensuring that experimental results have a high translational potential. By mirroring the heterogeneous nature of tumors, these models are uniquely positioned to unravel the complexities of tumor microenvironments and to test therapeutics in a context that is as close to clinical reality as possible. This introduction sets the stage for a comprehensive exploration of the PDX model market, its transformative shifts, key segmentation insights, regional dynamics, leading players, actionable recommendations, and strategic next steps.

Transformative Shifts Redefining the PDX Landscape

Recent years have witnessed transformative shifts in the PDX landscape that have redefined how researchers approach cancer modeling and drug development. New advancements in genomic characterizations and high-throughput screening techniques have allowed for a more nuanced capture of tumor heterogeneity. These innovations are fostering significant improvements in the establishment, maintenance, and analysis of PDX models. The integration of artificial intelligence and machine learning tools into these processes is further enhancing the precision with which data is interpreted, leading to expedited insights and refined experimental outcomes.

The growing emphasis on personalized medicine has catalyzed a paradigm shift, encouraging partnerships between academic institutions, oncology centers, and the pharmaceutical industry. Regulatory bodies are also evolving their guidelines to accommodate these innovative technologies, which in turn drives market confidence and investment. Enhanced operational efficiencies, along with improved methods for implantation and tracking, have led to a consolidation of best practices across research institutions. Overall, the transformative shifts observed in the PDX sector underscore the transition towards more sophisticated, reliable, and clinically relevant models, ensuring that the research community is better equipped to tackle the pressing challenges of cancer therapy and drug discovery.

Key Segmentation Insights Driving Market Dynamics

Market segmentation within the PDX modeling space plays a pivotal role in shaping strategies and identifying opportunities. A nuanced analysis based on the type of animal model reveals a primary division between mice models and rat models, each catering to specific research needs and experimental designs. Further, segmentation based on tumor type allows the study of diverse cancer subsets including those commonly found in the gastrointestinal tract, gynecological tissues, hematological systems, respiratory functions, and urological conditions. This diversity reflects the broad applicability of PDX models across varied oncological disciplines.

Segmentation by study type further extends the analytical framework into distinct categories that involve ex-vivo, in-vitro, and in-vivo research approaches. This layering ensures that each phase of preclinical investigation is tailored to the appropriate experimental conditions. Additionally, the implantation method is dissected into heterotopic, orthotopic, and subcutaneous approaches, each with its own merits and limitations in mimicking the clinical environment. When examining the application spectrum, the market is studied through diverse use cases such as basic cancer research, biomarker discovery, genomic and molecular studies, personalized medicine initiatives, preclinical drug evaluation, and the analysis of tumor microenvironment dynamics. Finally, segmentation by end-user identifies key consumption patterns among academic research institutes, dedicated cancer research centers, and pharmaceutical as well as biotechnology companies. These insights collectively drive market strategies and support informed decision-making at every level of research and development.

Based on Type, market is studied across Mice Models and Rat Models.

Based on Tumor Type, market is studied across Gastrointestinal, Gynecological, Hematological, Respiratory, and Urological.

Based on Study Type, market is studied across Ex-vivo, In-vitro, and In-vivo.

Based on Implantation Method, market is studied across Heterotopic, Orthotopic, and Subcutaneous.

Based on Application, market is studied across Basic Cancer Research, Biomarker Discovery, Genomic & Molecular Studies, Personalized Medicine, Preclinical Drug Evaluation, and Tumor Microenvironment Analysis.

Based on End-User, market is studied across Academic Research Institutes, Cancer Research Centers, and Pharmaceutical & Biotechnology Companies.

Key Regional Insights Shaping Market Expansion

Regional factors play a fundamental role in the strategic positioning and expansion of the PDX model market. In the Americas, the confluence of cutting-edge research facilities, robust funding mechanisms, and proactive regulatory environments creates fertile ground for innovation and the rapid adoption of PDX models. The market here benefits from extensive collaborations between academic institutions and major pharmaceutical companies, leading to accelerated translational research and more refined therapeutic strategies.

Across Europe, the Middle East, and Africa, there is an increasing trend towards interdisciplinary research efforts that integrate clinical insights with advanced biotechnological methods. Regulatory harmonization and strong public-private partnerships in these regions have further solidified the market’s growth trajectory. In the Asia-Pacific region, the dynamic landscape is characterized by significant investments in healthcare infrastructure and a growing focus on precision medicine. Rapid industrialization, coupled with government initiatives aimed at promoting research and development, has contributed to a vibrant market expansion. Collectively, these regional insights highlight how diverse economic conditions and health care infrastructures contribute to global market dynamics, each playing its part in fostering a sustainable growth environment in the PDX model sector.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Company Insights from Market Leaders

The PDX model market benefits significantly from the contributions of a diverse array of industry leaders. Major players include Abnova Corporation and Altogen Labs, which excel in innovative research techniques and model refinement. Biocytogen and BioDuro LLC, along with organizations such as BioReperia AB and Certis Oncology Solutions, have cemented their positions through unique technological capabilities and a forward-thinking approach. Other influential companies such as Champions Oncology, Inc. and Charles River Laboratories International, Inc. provide comprehensive model systems supported by robust preclinical data.

The industry landscape is further enriched by the specialized expertise of Creative Animodel and Creative Biolabs, which deliver tailored PDX solutions. Crown Bioscience by JSR Corporation and EPO Berlin-Buch GmbH are recognized for their advanced preclinical drug evaluation platforms. Emerging players such as GemPharmatech Co. Ltd. and Genesis Drug Discovery & Development inject fresh innovation into the market. Additionally, companies like Hera Biolabs, HOIST Co.,Ltd., InnoSer, and Inotiv, Inc. contribute significant expertise in refining PDX protocols. Laboratory Corporation of America Holdings and LIDE Shanghai Biotech, Ltd further expand the competitive landscape with strategic research collaborations. Mediford Corporation by PHC Holdings Corporation, Oncodesign Services, Shanghai ChemPartner, and Shanghai Medicilon Inc. continue to drive research excellence, while TheraIndx Lifesciences Pvt. Ltd., Urosphere SAS, WuXi AppTec Co., Ltd., and Xentech round out the market with their cutting-edge solutions. Their collective efforts and innovation are propelling the PDX market towards a more precise and personalized future in cancer research.

The report delves into recent significant developments in the Patient-Derived Xenograft/PDX Model Market, highlighting leading vendors and their innovative profiles. These include Abnova Corporation, Altogen Labs, Biocytogen, BioDuro LLC, BioReperia AB, Certis Oncology Solutions, Champions Oncology, Inc., Charles River Laboratories International, Inc., Creative Animodel, Creative Biolabs, Crown Bioscience by JSR Corporation, EPO Berlin-Buch GmbH, GemPharmatech Co. Ltd., Genesis Drug Discovery & Development, Hera Biolabs, HOIST Co.,Ltd., InnoSer, Inotiv, Inc., Laboratory Corporation of America Holdings, LIDE Shanghai Biotech, Ltd, Mediford Corporation by PHC Holdings Corporation, Oncodesign Services, Shanghai ChemPartner, Shanghai Medicilon Inc., TheraIndx Lifesciences Pvt. Ltd., Urosphere SAS, WuXi AppTec Co., Ltd., and Xentech.

Actionable Recommendations for Industry Leaders

Based on current market trends and the strategic shifts observed in PDX model research, industry leaders are encouraged to adopt a multi-pronged approach. First, expanding collaborative networks with academic institutions and regulatory bodies can accelerate the integration of advanced technologies, fostering a more adaptive research environment. Leaders should invest in robust data analytics and digital tools to enhance model reproducibility and predictive capabilities.

Furthermore, it is crucial to align research strategies with emerging applications in personalized medicine, ensuring that PDX models are leveraged to their fullest translational potential. Diversifying research portfolios to include both traditional tumor types and rarer subtypes can offer competitive advantages. Optimizing implantation methods and study types through continuous process improvement is another key recommendation. By embracing these strategies, industry players can secure a leadership position in an increasingly competitive market segment, thereby driving both innovation and sustainable growth.

The evolving landscape of the PDX model market underscores the increasing reliance on patient-specific research models that provide unparalleled insights into tumor biology and therapeutic response. Comprehensive examination of market segmentation reveals that diverse study designs, tumor types, implantation methods, applications, and end-user profiles collectively shape the innovation trajectory in this field. Regional dynamics further illustrate that while technological advancements and regulatory reforms are propelling the market in the Americas, Europe, the Middle East, Africa, and Asia-Pacific, a globally integrated approach is essential for sustained growth.

Industry leaders must adopt a proactive strategy that involves embracing technological innovation, fostering strategic partnerships, and continually refining research methodologies. Ultimately, the commitment to leveraging PDX models in drug discovery and personalized cancer therapy will define the future pathway of this vibrant market. The synthesis of research data and actionable insights presented herein serves as both a guide and a catalyst for those poised to make impactful decisions in the realm of translational oncology.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in cancer prevalence amplifying the need for advanced preclinical models to enhance drug discovery
5.1.1.2. Increased government initiatives and fundings for oncology research
5.1.1.3. Incorporation of PDX models in precision medicine for enhanced patient outcomes
5.1.2. Restraints
5.1.2.1. Concerns associated with instability and high-cost implications of PDX models
5.1.3. Opportunities
5.1.3.1. Strategic collaborations and partnership to accelerate cancer drug development
5.1.3.2. Integration of advanced analytical platforms with PDX models in drug testing
5.1.4. Challenges
5.1.4.1. Ethical concerns and regulations limiting the use of patient-derived xenograft models in research
5.2. Market Segmentation Analysis
5.2.1. Type: Genetic similarity enhances mice model's role in translational oncology research
5.2.2. Tumor Type: The ability of PDX models to closely mimic the human disease in genetic and phenotypic aspects increases the usage in hematological cancers
5.2.3. Study Type: In-vivo Models enhancing preclinical cancer research through accurate replication of human tumor biology
5.2.4. Implantation Method: The increasing adoption of subcutaneous implantation is driven by its simplicity and practicality in research settings
5.2.5. Application: PDX models advancing preclinical drug evaluation with accurate cancer simulation
5.2.6. End-User: Driving innovation in drug development with Patient-Derived Xenograft/PDX models in pharmaceutical and biotechnology companies
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Patient-Derived Xenograft/PDX Model Market, by Type
6.1. Introduction
6.2. Mice Models
6.3. Rat Models
7. Patient-Derived Xenograft/PDX Model Market, by Tumor Type
7.1. Introduction
7.2. Gastrointestinal
7.3. Gynecological
7.4. Hematological
7.5. Respiratory
7.6. Urological
8. Patient-Derived Xenograft/PDX Model Market, by Study Type
8.1. Introduction
8.2. Ex-vivo
8.3. In-vitro
8.4. In-vivo
9. Patient-Derived Xenograft/PDX Model Market, by Implantation Method
9.1. Introduction
9.2. Heterotopic
9.3. Orthotopic
9.4. Subcutaneous
10. Patient-Derived Xenograft/PDX Model Market, by Application
10.1. Introduction
10.2. Basic Cancer Research
10.3. Biomarker Discovery
10.4. Genomic & Molecular Studies
10.5. Personalized Medicine
10.6. Preclinical Drug Evaluation
10.7. Tumor Microenvironment Analysis
11. Patient-Derived Xenograft/PDX Model Market, by End-User
11.1. Introduction
11.2. Academic Research Institutes
11.3. Cancer Research Centers
11.4. Pharmaceutical & Biotechnology Companies
12. Americas Patient-Derived Xenograft/PDX Model Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Patient-Derived Xenograft/PDX Model Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Patient-Derived Xenograft/PDX Model Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
15.3.1. Certis Oncology unveils AI-driven chatbot to enhance cancer research insights and PDX model efficiency
15.3.2. UCLB and CancerTools.org partnership enhances new NSCLC PDX models development
15.3.3. Champions Oncology announces licensing agreement with Weill Cornell Medicine
15.3.4. REM-422 demonstrates tumor regression in ACC PDX models at 2024 symposium
15.3.5. Charles River Laboratories transforming oncology research with PDX models and digital twins at AACR 2024
15.3.6. Crown Bioscience has announced new preclinical and translational oncology data at the AACR 2024
15.3.7. ProteinQure unveils breakthrough PDC showcasing exceptional efficacy in diverse PDX models
15.3.8. InVivo Biosystems and BioReperia partners to transform cancer drug development
15.3.9. Kiyatec and XenoSTART collaborated to help reduce drug development costs
15.3.10. Soteria Precision Medicine Foundation partners with Certis Oncology Solutions
15.4. Strategy Analysis & Recommendation
15.4.1. WuXi AppTec Co., Ltd.
15.4.2. Crown Bioscience by JSR Corporation
15.4.3. Mediford Corporation by PHC Holdings Corporation
15.4.4. Charles River Laboratories International, Inc.
List of Figures
FIGURE 1. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET MULTI-CURRENCY
FIGURE 2. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET MULTI-LANGUAGE
FIGURE 3. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET RESEARCH PROCESS
FIGURE 4. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2023 VS 2030
FIGURE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2023 VS 2030 (%)
FIGURE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2023 VS 2030 (%)
FIGURE 15. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 17. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 19. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 23. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 25. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 28. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 29. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET DYNAMICS
TABLE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 54. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 55. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 56. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 57. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 58. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 59. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 61. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 62. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 63. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 64. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 65. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 80. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 85. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 86. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 87. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 88. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 89. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 90. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 91. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 92. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 93. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 94. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 95. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 96. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 97. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 98. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 101. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 102. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 103. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 104. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 105. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 106. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 107. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 108. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 109. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 110. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 114. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 115. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 116. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 119. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 120. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 121. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 122. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 125. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 126. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 128. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 131. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 132. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 133. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 134. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 137. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 138. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 140. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 141. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 142. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 143. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 144. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 146. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 147. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 149. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 150. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 151. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 159. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 160. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 161. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 162. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 163. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 164. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 165. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 166. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 167. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 168. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 169. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 170. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 171. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 172. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 173. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 174. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 175. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 176. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 177. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 178. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 179. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 180. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 181. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 182. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 183. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 184. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 185. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 186. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 187. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 189. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 192. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 193. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 194. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 195. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 196. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 197. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 198. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 199. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 200. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 213. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 214. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 215. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 216. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 217. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 218. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 219. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 220. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 221. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 222. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 223. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 224. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 225. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 226. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 227. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 228. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 229. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 230. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 236. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 248. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 249. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 250. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 251. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 252. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 253. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 260. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 266. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 267. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 268. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 269. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 270. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 271. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 272. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
TABLE 282. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 284. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 285. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2023
TABLE 286. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

  • Abnova Corporation
  • Altogen Labs
  • Biocytogen
  • BioDuro LLC
  • BioReperia AB
  • Certis Oncology Solutions
  • Champions Oncology, Inc.
  • Charles River Laboratories International, Inc.
  • Creative Animodel
  • Creative Biolabs
  • Crown Bioscience by JSR Corporation
  • EPO Berlin-Buch GmbH
  • GemPharmatech Co. Ltd.
  • Genesis Drug Discovery & Development
  • Hera Biolabs
  • HOIST Co.,Ltd.
  • InnoSer
  • Inotiv, Inc.
  • Laboratory Corporation of America Holdings
  • LIDE Shanghai Biotech, Ltd
  • Mediford Corporation by PHC Holdings Corporation
  • Oncodesign Services
  • Shanghai ChemPartner
  • Shanghai Medicilon Inc.
  • TheraIndx Lifesciences Pvt. Ltd.
  • Urosphere SAS
  • WuXi AppTec Co., Ltd.
  • Xentech

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages189
PublishedMarch 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 429.04 Million
Forecasted Market Value ( USD ) by 2030 $ 862.31 Million
Compound Annual Growth Rate12.2%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Patient Derived Xenograft (PDX) Models Market Report 2024 - Product Image

Patient Derived Xenograft (PDX) Models Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Patient Derived Xenograft / PDX Models - Global Strategic Business Report - Product Image

Patient Derived Xenograft / PDX Models - Global Strategic Business Report

  • Report
  • 310 Pages
  • Global
From
Patient-derived Xenograft Model Market Size, Share & Trends Analysis Report By Tumor Type (Lung Cancer, Breast Cancer), By Model Type (Mice Model, Rat Model), By End Use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Patient-derived Xenograft Model Market Size, Share & Trends Analysis Report By Tumor Type (Lung Cancer, Breast Cancer), By Model Type (Mice Model, Rat Model), By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Oncology Based In-Vivo CRO Market Report by Indication (Blood Cancer, Solid Tumors, and Others), Model (Syngeneic, Xenograft, Patient Derived Xenograft (PDX), and Others), Application (Hospitals, Rehabilitation Centers), and Region 2024-2032 - Product Image

Oncology Based In-Vivo CRO Market Report by Indication (Blood Cancer, Solid Tumors, and Others), Model (Syngeneic, Xenograft, Patient Derived Xenograft (PDX), and Others), Application (Hospitals, Rehabilitation Centers), and Region 2024-2032

  • Report
  • 135 Pages
  • Global
From
2024 Global Forecast for Patient Derived Xenograft (Pdx) Models Market (2025-2030 Outlook)-High Tech & Emerging Markets Report - Product Image

2024 Global Forecast for Patient Derived Xenograft (Pdx) Models Market (2025-2030 Outlook)-High Tech & Emerging Markets Report

  • Report
  • 132 Pages
  • Global
From

About the Patient Derived Xenograft Market

The Patient Derived Xenograft (PDX) market is a rapidly growing segment of the drug discovery industry. PDX models are derived from human tumors that are implanted into immunodeficient mice, allowing researchers to study the effects of drugs on human cancer in a living system. PDX models are used to identify new drug targets, evaluate drug efficacy, and assess drug safety. They are also used to study the biology of cancer and to develop personalized treatments. PDX models are increasingly being used in clinical trials to evaluate the efficacy of new drugs. PDX models offer several advantages over traditional cell-based models, including the ability to study the effects of drugs on a living system, the ability to study the effects of drugs on multiple tumor types, and the ability to study the effects of drugs on the tumor microenvironment. Companies in the PDX market include Charles River Laboratories, Crown Bioscience, Horizon Discovery, and Taconic Biosciences. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.